

**Table S5**

Sensitivity analyses for secondary switch (backswitch group, n=28)

<b>Switch distance</b>				
<b>Primary-switch-distance between last A<sup>a</sup>/R<sup>b</sup> and first B<sup>c</sup> [in days]</b>	81.1± 5.8			
<b>Secondary-switch-distance between last A<sup>a</sup>/R<sup>b</sup> and first B<sup>c</sup> [in days]</b>	52.0± 3.5			
<b>Drug exposure</b>	<b>before switch</b>	<b>after switch</b>	<b>before switchback</b>	<b>after switchback</b>
<b>Therapy time [in years]</b>	3.1± 0.5	0.5± 0.07	0.5± 0.07	0.8± 0.09
<b>Number of IVT-injections</b>	17.7± 2.5	5.6± 0.5	5.6± 0.5	7.9± 0.8
<b>Interval between last two recorded IVT-injections [in days]</b>	33.9± 2.2	33.9± 2.0	33.9± 2.0	49.5± 6.0
<b>Assigned finding distances</b>	<b>before switch</b>	<b>after switch</b>	<b>before switchback</b>	<b>after switchback</b>
<b>IVT-injection to BCVA distance [in days]</b>	36.1± 3.2	34.9± 2.5	32.4± 1.1	39.2± 3.1
<b>IVT-injection to OCT distance [in days]</b>	34.9± 3.0	34.9± 2.5	32.1± 1.0	37.7± 2.6

<sup>a</sup>A, aflibercept; <sup>b</sup>R, ranibizumab; <sup>c</sup>B, bevacizumab

